Utepreva LLC today announced the launch of the Utepreva Endometrial Sampler, a patented, FDA 510(k)-cleared, single-use endometrial sampling device engineered to enhance tissue capture and support ...

ACOG issued updated guidance recommending endometrial tissue sampling as well as transvaginal ultrasonography when initially ...

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.

In this study, researchers aimed to identify endometrial cancer patient preferences and gather insights on how these preferences might inform treatment decisions.

Women who have abnormal bleeding after menopause typically undergo a non-invasive procedure — a transvaginal ultrasound — to look for signs of uterine cancer. But research suggests that test misses ...

The data from Part 1 of the ongoing global Phase 1 study ( ZWI-ZW191-101 ), highlight a compelling combination of anti-tumor activity and manageable safety in patients with advanced, heavily ...

Recurrent/metastatic EC has a poor long-term prognosis, and treatment options are limited beyond first line, said Pothuri.

“Endometrial cancer treatment generally has a high success rate, especially when the cancer is found early,” says John Wallbillich, MD, gynecologic oncologist at the Barbara Ann Karmanos Cancer ...

Although it is known that obesity increases the risk of endometrial cancer and is linked to higher mortality rates in the general population, the association between obesity and mortality among ...